Investing

Arcus Biosciences : RCUS

RCUS

Stock Data

$21.95

$0.15 (0.69%)

Asset Type

Common Stock

Exchange

NYSE

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Arcus Biosciences is a pioneering biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. With a robust pipeline that includes treatments like Domvanalimab and AB308 for advanced cancers, and Etrumadenant for dual adenosine receptor antagonism, the company is at the forefront of clinical trials aimed at combating various malignancies. Additionally, Arcus is exploring treatments for inflammatory diseases in collaboration with industry leaders, demonstrating its commitment to advancing healthcare through groundbreaking research.

All Arcus Biosciences Articles

3 Articles

Trey Thoelcke | Feb 23, 2025 at 8:45 AM EST

Biotechs Highlight 6 Stocks Insiders Are Buying Now

Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a…

Trey Thoelcke | Feb 5, 2024 at 12:09 PM EST

Insider Buying at These Biotechs Is Huge

As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at…

Jon C. Ogg | May 27, 2020 at 3:36 PM EDT

With Arcus Partnership vs. Buyout, Gilead Moves Beyond Remdesivir COVID-19 Focus

In a world where investors are starving to find growth, many of the well established biotech leaders and many of…